| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(8 years from now) | |
Bortezomib is owned by Fresenius Kabi Usa.
Bortezomib contains Bortezomib.
Bortezomib has a total of 1 drug patent out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 06 November, 2017.
Bortezomib is available in powder;intravenous dosage forms.
The generics of Bortezomib are possible to be released after 03 November, 2032.
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BORTEZOMIB family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
| US11752164 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
Bortezomib is owned by Maia Pharms Inc.
Bortezomib contains Bortezomib.
Bortezomib has a total of 2 drug patents out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 27 July, 2022.
Bortezomib is available in solution;intravenous dosage forms.
Bortezomib can be used as treatment of adult patients with multiple myeloma.
The generics of Bortezomib are possible to be released after 23 September, 2042.
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma
Dosage: SOLUTION;INTRAVENOUS
BORTEZOMIB family patents